OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae‐Weon Kim, Richard T. Penson, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 50-62
Open Access | Times Cited: 30
Yvette Drew, Jae‐Weon Kim, Richard T. Penson, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 50-62
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 46
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 46
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Giorgio Bogani, Kathleen Moore, I. L. Ray-Coquard, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 30-40
Closed Access | Times Cited: 7
Giorgio Bogani, Kathleen Moore, I. L. Ray-Coquard, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 30-40
Closed Access | Times Cited: 7
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 16
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 16
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 15
Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 15
Recent Therapeutic Advances in Gynecologic Oncology: A Review
Elise Wilson, Ramez N. Eskander, Pratibha Binder
Cancers (2024) Vol. 16, Iss. 4, pp. 770-770
Open Access | Times Cited: 12
Elise Wilson, Ramez N. Eskander, Pratibha Binder
Cancers (2024) Vol. 16, Iss. 4, pp. 770-770
Open Access | Times Cited: 12
PARPi, BRCA, and gaps: controversies and future research
Diego Dibitetto, Carmen A. Widmer, Sven Rottenberg
Trends in cancer (2024) Vol. 10, Iss. 9, pp. 857-869
Open Access | Times Cited: 11
Diego Dibitetto, Carmen A. Widmer, Sven Rottenberg
Trends in cancer (2024) Vol. 10, Iss. 9, pp. 857-869
Open Access | Times Cited: 11
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
The Landscape of PARP Inhibitors in Solid Cancers
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Fen Xiao, Zhibin Wang, Qiao Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Fen Xiao, Zhibin Wang, Qiao Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W. Garsed, George Au‐Yeung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Nadja Stiegeler, Dale W. Garsed, George Au‐Yeung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Strategies for the prevention or reversal of PARP inhibitor resistance
Zahi Mitri, Shaun Goodyear, Gordon B. Mills
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 10, pp. 959-975
Open Access | Times Cited: 4
Zahi Mitri, Shaun Goodyear, Gordon B. Mills
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 10, pp. 959-975
Open Access | Times Cited: 4
Role of PARP inhibitors in ovarian cancer
Antonio Casado da Rocha, M. Marrero, Marina García, et al.
Revisiones en Cáncer (2025)
Closed Access
Antonio Casado da Rocha, M. Marrero, Marina García, et al.
Revisiones en Cáncer (2025)
Closed Access
Pharmacological targeting of PD-L1/PD-1 signaling in gynecological cancers
Ammad Ahmad Farooqı, Gürkan Özbey, Sundas Fayyaz, et al.
Postępy Higieny i Medycyny Doświadczalnej (2025) Vol. 79, Iss. 1, pp. 25-34
Open Access
Ammad Ahmad Farooqı, Gürkan Özbey, Sundas Fayyaz, et al.
Postępy Higieny i Medycyny Doświadczalnej (2025) Vol. 79, Iss. 1, pp. 25-34
Open Access
Global Burden of Thyroid Cancer in Children and Adolescents, 1990–2021: Trends, Disparities, and Future Projections
Tianyu Li, Zhen Cao, Lin Chen, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 892-892
Open Access
Tianyu Li, Zhen Cao, Lin Chen, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 892-892
Open Access
Ovarian cancer: Advances in clinical research
Mahendra Saini, Nidhi Chauhan, Afrasim Moin, et al.
Elsevier eBooks (2025), pp. 221-250
Closed Access
Mahendra Saini, Nidhi Chauhan, Afrasim Moin, et al.
Elsevier eBooks (2025), pp. 221-250
Closed Access
Ovarian cancer targeted therapy: current landscape and future challenges
Guangli Wang, Hui Yang, Yuling Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Guangli Wang, Hui Yang, Yuling Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab
Ashkan Adibi, Ünal Metin Tokat, Esranur Aydın, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 184-190
Open Access
Ashkan Adibi, Ünal Metin Tokat, Esranur Aydın, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 184-190
Open Access
Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials
Cecilia Nasso, Silvia Puglisi, Sara Elena Rebuzzi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Cecilia Nasso, Silvia Puglisi, Sara Elena Rebuzzi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
Raphael Gronauer, Leonie Madersbacher, Pablo Monfort‐Lanzas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Raphael Gronauer, Leonie Madersbacher, Pablo Monfort‐Lanzas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
Giada De Lazzari, Alena Opattová, Sabrina Arena
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Giada De Lazzari, Alena Opattová, Sabrina Arena
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
Aleksandra Romaniuk-Drapała, Paulina Skupin-Mrugalska, Olga B. Garbuzenko, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Aleksandra Romaniuk-Drapała, Paulina Skupin-Mrugalska, Olga B. Garbuzenko, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
ADC: a deadly killer of platinum resistant ovarian cancer
Cheng Xu, Ping Li, Rongqi Jiang, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Cheng Xu, Ping Li, Rongqi Jiang, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 2
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 8, pp. 1225-1231
Closed Access | Times Cited: 1
Agnieszka Michael, William Wilson, Sunny Sunshine, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 8, pp. 1225-1231
Closed Access | Times Cited: 1
Past and present: a bibliometric study on the treatment of recurrent ovarian cancer
Xiao-yuan Hao, Wen-wei Song, Miaoling Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Xiao-yuan Hao, Wen-wei Song, Miaoling Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies
Rong Wang, Yunxi Liu, Mingqi Liu, et al.
International Journal of Pharmaceutics (2024) Vol. 669, pp. 125028-125028
Closed Access | Times Cited: 1
Rong Wang, Yunxi Liu, Mingqi Liu, et al.
International Journal of Pharmaceutics (2024) Vol. 669, pp. 125028-125028
Closed Access | Times Cited: 1
